
Research ArticleA randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
Keywords: HCV; hepatitis C virus; NS5A; nonstructural protein 5A; DAA; direct-acting antiviral agent; EC50; 50% effective concentration; CYP; cytochrome P450; HBV; hepatitis B virus; HIV; human immunodeficiency virus; QD; once daily; BID; twice daily; AE; adverse e